<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">NM</journal-id><journal-title-group><journal-title>Neuroscience &amp; Medicine</journal-title></journal-title-group><issn pub-type="epub">2158-2912</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/nm.2013.42016</article-id><article-id pub-id-type="publisher-id">NM-33257</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Tuberculous Meningitis: Diagnostic and Radiological Features, Pathogenesis and Biomarkers
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>ei-Ling</surname><given-names>Sharon Tai</given-names></name><xref ref-type="aff" rid="aff1"><sub>1</sub></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>sharont1990@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>06</month><year>2013</year></pub-date><volume>04</volume><issue>02</issue><fpage>101</fpage><lpage>107</lpage><history><date date-type="received"><day>February</day>	<month>12th,</month>	<year>2013</year></date><date date-type="rev-recd"><day>March</day>	<month>26th,</month>	<year>2013</year>	</date><date date-type="accepted"><day>April</day>	<month>25th,</month>	<year>2013</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   Central nervous system tuberculosis is the most severe form of extrapulmonary tuberculosis disease. We aim to review the diagnostic and radiological features, pathogenesis, and biomarkers of tuberculous meningitis. We also aim to look at the latest development of research of the disease. The diagnosis of tuberculous (TB) meningitis is difficult because the disease presents with unspecific clinical features. However, the disease has excellent clinical response to antituberculous therapy. Good prognosis depends on prompt diagnosis with treatment and radiological findings are very important. There is an increase in the levels of serum and cerebrospinal fluid (CSF) TNF-in TB meningitis patients. IL-6 level is also increased in patients with tuberculoma and exudates. There is an increase in the levels of serum and CSF TNF-α and IFN-γ in TB meningitis patients. There is also a rise in the levels of IL-8, IFN-alpha, IFN-gamma, IL-10, CSF matrix metalloproteinases, CSF tissue inhibitors of matrix Metalloproteinases, VEGF level, caspase-1 and IL-1β. Signal-regulatory protein alpha is overexpressed at mRNA level. High dose intravenous rifampicin (800 mg daily) is associated with reduced mortality in patients with advanced disease. 
 
</p></abstract><kwd-group><kwd>Tuberculous Meningitis; TB; Infection; Cerebrospinal Fluid</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Tuberculosis (TB) is a major health and clinical problem in the world [1-3]. There are eight million new cases annually [<xref ref-type="bibr" rid="scirp.33257-ref2">2</xref>]. The disease also results in three million deaths [<xref ref-type="bibr" rid="scirp.33257-ref2">2</xref>]. 15% of all tuberculous infections are extra-pulmonary [<xref ref-type="bibr" rid="scirp.33257-ref2">2</xref>]. Extra-pulmonary TB consists of TB lymphadenitis, genitourinary TB, central nervous system TB and others [<xref ref-type="bibr" rid="scirp.33257-ref2">2</xref>]. Central nervous system tuberculosis is the most severe form of extrapulmonary tuberculosis disease [1,4-6]. Central nervous system tuberculosis includes tuberculous meningitis (TBM) which occurs in 4% of all cases [<xref ref-type="bibr" rid="scirp.33257-ref2">2</xref>]. Extrapulmonary involvement can occur in isolation or along with a pulmonary TB in the patients with disseminated tuberculosis [<xref ref-type="bibr" rid="scirp.33257-ref1">1</xref>]. We aim to review the diagnostic features, pathogenesis, radiological features, biomarkers and treatment of tuberculous meningitis. The other objective is also to look at the latest progress of development of research of the disease.</p></sec><sec id="s2"><title>2. Body</title><sec id="s2_1"><title>2.1. Diagnosis</title><p>The diagnosis of TB meningitis is difficult because TB meningitis presents with unspecific symptoms and signs [4,7]. Later in the disease, confusion, change in behavior, seizures and cranial nerve palsies can develop [<xref ref-type="bibr" rid="scirp.33257-ref4">4</xref>]. The difficult diagnosis of TB meningitis is also due to haematogenous spread of the tubercle bacillus [<xref ref-type="bibr" rid="scirp.33257-ref1">1</xref>]. Therefore, early diagnosis and treatment of the disease is very important as the disease can result in mortality [1,3,4,7,8]. However, the other factor that makes diagnosis difficult is the small number of bacilli in the CSF which reduce the sensitivity of conventional bacteriology [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>]. In addition, the reason for early diagnosis is excellent clinical response to antituberculous drugs [<xref ref-type="bibr" rid="scirp.33257-ref1">1</xref>].</p><p>Diagnosis is based on the characteristic clinical features, radiological abnormalities, cerebrospinal fluid changes (acid-fast bacilli by direct staining of CSF or positive culture of acid-fast bacilli from CSF) [<xref ref-type="bibr" rid="scirp.33257-ref9">9</xref>] and the response (clinical and CSF) to anti-tuberculosis medications [<xref ref-type="bibr" rid="scirp.33257-ref1">1</xref>]. In addition to clinical features and radiological features, pathological features and biomarkers also help with the diagnosis of TB meningitis.</p></sec><sec id="s2_2"><title>2.2. Clinical Features</title><p>The clinical features are fever for more than seven days, headache, and neck stiffness [1,6,10-12]. The other common clinical features are vomiting, focal neurological deficits, vision loss, cranial nerve palsies and raised intracranial pressure [5,13]. In human immunodeficiency virus (HIV) infection, TB is often atypical in presentation, frequently causing extrapulmonary disease, and patients have a high incidence of TB meningitis [1,5].</p><p>Presence of recent exposure to tuberculosis and signs of active extrameningeal tuberculosis on clinical assessment is important [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>]. Chest radiography reveals active TB, previous tuberculosis infection or military TB in 50% of patients with TB meningitis [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>]. Mantoux test, which is skin testing with purified protein derivative of M. tuberculosis is of limited value in adults [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>].</p><p>A diagnostic rule based on age (less than 36 years old), white blood cell count (less than 15,000), duration of illness (less than six days), cerebrospinal fluid white cell count (less than 750) and percentage of neutrophils in the CSF (less than 90%) had 86% sensitivity and 79% specificity [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>]. There is a higher risk of TB meningitis with score of ≤4, and lower probability of TB meningitis when the score is more than four [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>]. Basal meningeal enhancement, tuberculoma, or both, were 89% sensitive and 100% specific for the diagnosis of TB meningitis [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>].</p><p>The diagnosis of TB meningitis is limited by the poor sensitivity of CSF microscopy. In addition, Mycobacterium tuberculosis (M. tuberculosis) culture takes a few months to come back [<xref ref-type="bibr" rid="scirp.33257-ref3">3</xref>]. A study demonstrated that acid-fast bacilli was seen in 58% of patients, and cultured from 71% of the patients [<xref ref-type="bibr" rid="scirp.33257-ref14">14</xref>].</p><p>M. tuberculosis nucleic acid amplification PCR can be used for rapid diagnosis of TB meningitis [1,3]. Real time PCR allows direct observation of amplicon reaction [<xref ref-type="bibr" rid="scirp.33257-ref3">3</xref>]. PCR tests are more sensitive and specific in detection of specific DNA sequences [<xref ref-type="bibr" rid="scirp.33257-ref1">1</xref>].</p><p>In a recent study, IS6110-PCR had the highest positivity rate (68%) in comparison to Ziehl-Neelsen microscopy (11%) and mycobacterial culture (36% - 44%) [<xref ref-type="bibr" rid="scirp.33257-ref3">3</xref>]. In 92% of patients with culture-positive, CSF IS6110- PCR was positive, whereas in culture-negative probable TB meningitis CSF TB IS6110-PCR was positive in 42% of patients [<xref ref-type="bibr" rid="scirp.33257-ref3">3</xref>]. For qRT-PCR (filtrate), the sensitivity is 87.6% and specificity is 92% [<xref ref-type="bibr" rid="scirp.33257-ref15">15</xref>]. In comparison, the sensitivity for IS6110-PCR (filtrate) is 85.2% and the specificity is 83.7% [<xref ref-type="bibr" rid="scirp.33257-ref15">15</xref>].</p><p>BACTEC MGIT 960 can be used as a rapid test for the diagnosis of TB meningitis [<xref ref-type="bibr" rid="scirp.33257-ref16">16</xref>]. The sensitivity of BACTEC MGIT 960 is 81.5% and specificity is 99.6% [<xref ref-type="bibr" rid="scirp.33257-ref16">16</xref>].</p><p>A recent study reported that the ELISA test for Mycobacterium tuberculosis anti-antigen A60 antibodies (IgM) is a rapid and sensitive tool for the rapid diagnosis of TBM [<xref ref-type="bibr" rid="scirp.33257-ref17">17</xref>]. This test can be used in addition to adenosine deaminase (ADA) determination [<xref ref-type="bibr" rid="scirp.33257-ref17">17</xref>]. The two tests are limited by poor specificities (80%) [<xref ref-type="bibr" rid="scirp.33257-ref17">17</xref>]. The sensitivity of anti-A60 IgM CSF antibody titres was 94% compared to 88% [<xref ref-type="bibr" rid="scirp.33257-ref17">17</xref>].</p><p>The cerebrospinal fluid (CSF) shows a high CSF white-cell count, which is predominantly lymphocytic, with a high protein and low glucose level (CSF plasma glucose is &lt;50%) [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>]. Total CSF white cell count can be normal in those with TB meningitis, especially in the people with depressed cell-mediated immunity, such as the elderly and HIV patients [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>]. Low CSF white cell counts have been associated with worse outcome [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>].</p><p>Neutrophils can be the predominant cells, especially early in the disease, and high proportions of neutrophils in the cell count have been associated with improved survival [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>].</p><p>Multiple CSF sampling improves the sensitivity of Ziehl-Neelsen stain to more than 80% [<xref ref-type="bibr" rid="scirp.33257-ref18">18</xref>]. In addition, the chance of culturing M. tuberculosis from CSF depends on culture of a large volume (more than 5 mL) of CSF [<xref ref-type="bibr" rid="scirp.33257-ref14">14</xref>].</p><p>The severity of TB meningitis at presentation is divided into three stages according to the patient’s Glasgow coma score and the presence/absence of focal neurological signs [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>].</p><p>Movement disorders can present after basal ganglia stroke [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>]. The most common movement disorder is tremor. The others are chorea, ballismus, and myoclonus [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>].</p></sec><sec id="s2_3"><title>2.3. Pathology</title><p>Pathologically from autopsies, there was a subcortical or meningeal focus (“Rich focus”) from which bacteria had access to the subarachnoid space [<xref ref-type="bibr" rid="scirp.33257-ref17">17</xref>]. After the release of bacteria and granuloma into the subarachnoid space, a dense inflammatory exudate forms [<xref ref-type="bibr" rid="scirp.33257-ref17">17</xref>]. The inflammatory exudate that affects mostly the sylvian fissures, basal cisterns, brainstem, and cerebellum [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>]. The gelatinous basal meningeal exudate is also found at the interpeduncular fossa involving the optic nerves, the internal carotid arteries and suprasellar region anteriorly [19,20].</p><p>TB meningitis can also result in infiltrative, proliferative and necrotising vessel pathologies causing luminal thrombosis [<xref ref-type="bibr" rid="scirp.33257-ref21">21</xref>]. Vasospasm may mediate strokes early in the course of the disease and proliferative intimal disease cause stroke later on [<xref ref-type="bibr" rid="scirp.33257-ref21">21</xref>].<sup> </sup>In addition, the prothrombotic condition in TB meningitis could contribute to stroke [<xref ref-type="bibr" rid="scirp.33257-ref23">23</xref>].</p></sec><sec id="s2_4"><title>2.4. Radiological Features</title><p>Good prognosis depends on prompt diagnosis and treatment; therefore the importance of radiological findings is emphasized [<xref ref-type="bibr" rid="scirp.33257-ref2">2</xref>]. When a patient presents with a suspicion of TB meningitis, CT and MRI can be used to support the diagnosis and to look at the abnormalities of the brain and spine [2,8]. Early brain CT can help diagnose TB meningitis will provide important baseline information regarding surgical interventions for hydrocephalus [<xref ref-type="bibr" rid="scirp.33257-ref24">24</xref>].</p><p>MRI is also useful to monitor the development of complications of disease [<xref ref-type="bibr" rid="scirp.33257-ref2">2</xref>]. Brain MRI is better than CT in revealing brainstem and cerebellum pathology, tuberculomas, strokes, and the extent of inflammatory exudates [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>]. Precontrast hyperdensity in the basal cisterns might be the most specific radiological sign of TM in children [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>].</p><p>Stroke in tuberculous meningitis (TBM) occurs in 15% - 57% of patients especially in advanced stage and severe disease [<xref ref-type="bibr" rid="scirp.33257-ref25">25</xref>]. Magnetic resonance imaging (MRI) is more sensitive in detecting strokes in particular, acute stroke with diffusion weighted imaging (DWI) [<xref ref-type="bibr" rid="scirp.33257-ref25">25</xref>].</p><p>Bilaterally symmetrical strokes of the TB zone were common with TB meningitis (71%) but rare with noninflammatory ischemic stroke (IS) (5%) [<xref ref-type="bibr" rid="scirp.33257-ref23">23</xref>]. Most of the strokes in TBM are multiple, bilateral and located in the basal ganglia [<xref ref-type="bibr" rid="scirp.33257-ref25">25</xref>].</p><p>The locations of strokes were studied in 14 patients with TB meningitis and 173 patients with noninflammatory ischemic stroke (IS) in a study in Taiwan [<xref ref-type="bibr" rid="scirp.33257-ref23">23</xref>]. In patients with TBM, 75% of strokes were in the “TB zone” supplied by medial striate and thalamoperforating arteries; as compared to only 11% occurred in the “IS zone” supplied by lateral striate, anterior choroidal and thalamogeniculate arteries [<xref ref-type="bibr" rid="scirp.33257-ref23">23</xref>]. In patients with IS, 29% of strokes occurred in the IS zone, 29% in the subcortical white matter, and 24% in the cerebral cortex [<xref ref-type="bibr" rid="scirp.33257-ref23">23</xref>]. Only 11% occurred in the TB zone [<xref ref-type="bibr" rid="scirp.33257-ref23">23</xref>].</p><p>MRI features of stroke due to TBM are divided into anterior (caudate, genu, anterior limb of internal capsule, anteromedial thalamus) and posterior (lentiform nuclei, posterior limb of internal capsule, posterolateral thalamus) [<xref ref-type="bibr" rid="scirp.33257-ref26">26</xref>]. Cortical strokes can occur rarely because of involvement of proximal portion of the middle, anterior and posterior cerebral arteries, in addition to the supraclinoid part of the internal carotid and basilar arteries [<xref ref-type="bibr" rid="scirp.33257-ref25">25</xref>].</p><p>Choroid plexus enhancement with ventricular enlargement on imaging is highly suggestive of TBM [<xref ref-type="bibr" rid="scirp.33257-ref24">24</xref>]. In TBM, MRI shows diffuse, thick, meningeal enhancement [<xref ref-type="bibr" rid="scirp.33257-ref24">24</xref>]. Contrast enhanced MRI is generally considered as the modality of choice [<xref ref-type="bibr" rid="scirp.33257-ref27">27</xref>]. It is useful for assessment of the location of lesions and their margins, as well as ventriculitis, meningitis and spinal involvement (sensitivity 86%, specificity 90%) [<xref ref-type="bibr" rid="scirp.33257-ref27">27</xref>]. A large lipid, lactate peak has been used to specifically identify tuberculomas by magnetic resonance spectroscopy [<xref ref-type="bibr" rid="scirp.33257-ref28">28</xref>].</p><p>In summary, the typical changes of TB meningitis are hydrocephalus, tuberculomas, basal cistern, sylvian fissure and gyral enhancement, with stroke at areas supplied by medial striate and thalamoperforating arteries [2,13].</p></sec><sec id="s2_5"><title>2.5. Biochemical Markers</title><p>The release of Mycobacterium tuberculosis into the subarachnoid space results in a local T-lymphocyte-dependent response [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>]. T-lymphocyte-dependent response is characterised macroscopically as caseating granulomatous inflammation [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>].</p><p>In pulmonary tuberculosis, tumour necrosis factor (TNF) is believed to be important for granuloma formation [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>]. TNF is also a main factor in host-mediated destruction of infected tissue [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>]. Study of animal models of TB meningitis found that high CSF concentrations were associated with poorer outcome [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>]. In a series of 16 patients with TB meningitis, TNF-α is found in 32% of patients [<xref ref-type="bibr" rid="scirp.33257-ref29">29</xref>]. Another case series reported that there was a tremendous increase in the levels of serum and CSF TNF-α in TB meningitis patients compared to 20 age and sex-matched controls [<xref ref-type="bibr" rid="scirp.33257-ref30">30</xref>].</p><p>Protein levels of interleukin-6 (IL-6) were increased in patients who had presence of tuberculoma and increasing exudates [<xref ref-type="bibr" rid="scirp.33257-ref29">29</xref>]. The cytokine levels however did not significantly correlate with stage of meningitis, clinical outcome and radiological imaging [<xref ref-type="bibr" rid="scirp.33257-ref29">29</xref>].</p><p>TB meningitis results in bacteria replication, which caused an increase in IL-8, interferon-alpha (IFN-alpha) and IFN-gamma [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>]. The replication of the organism also caused a rise in CSF white blood cells (neutrophils and lymphocytes) and IL-10 [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>]. There is also an increase in the level of CSF matrix metalloproteinases and CSF tissue inhibitors of matrix Metalloproteinases [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>]. This results in increased CSF lactate and CSF protein, with reduced CSF glucose and breakdown of blood brain barrier [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>].</p><p>In addition, other cytokines, such as, IL-6, IL-10, and IL-1β are significantly higher in patients compared to controls, and the levels are reduced after three months of antituberculous therapy [<xref ref-type="bibr" rid="scirp.33257-ref29">29</xref>]. Levels of IL-6 are increased in patients with tuberculoma and worsening of exudates [<xref ref-type="bibr" rid="scirp.33257-ref29">29</xref>].</p><p>Serum and CSF IFN-γ levels are significantly associated with a marked rise in TB meningitis patients [<xref ref-type="bibr" rid="scirp.33257-ref30">30</xref>]. An increase in TNF-α and IFN-γ levels, especially in CSF, despite that these patients have multidrug therapy suggests the persistence of central nervous system inflammation [<xref ref-type="bibr" rid="scirp.33257-ref30">30</xref>]. The continuous release of cytokines despite these patients undergoing anti-tubercular therapy suggests that TBM severity may result mainly from the immune response rather than the organism itself [<xref ref-type="bibr" rid="scirp.33257-ref30">30</xref>].</p><p>Nitric oxide (NO) causes vascular and perivascular inflammatory central nervous system changes, which are possible aetiologies of tuberculous encephalopathy [<xref ref-type="bibr" rid="scirp.33257-ref20">20</xref>]. The nitric oxide (NO) levels of serum and CSF are higher significantly in TB meningitis patients [<xref ref-type="bibr" rid="scirp.33257-ref30">30</xref>]. There is no correlation between NO levels and severity of TB meningitis [<xref ref-type="bibr" rid="scirp.33257-ref30">30</xref>].</p><p>Neutrophils have a role in pathogenesis of TB meningitis [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>]. The lymphocyte response, mainly the roles of different lymphocyte subsets are also important [<xref ref-type="bibr" rid="scirp.33257-ref8">8</xref>].</p><p>Signal-regulatory protein alpha (SIRPA) and protein disulfide isomerase family A, member 6 (PDIA6), is overexpressed at the mRNA level in TB meningitis [<xref ref-type="bibr" rid="scirp.33257-ref31">31</xref>]. The proteins, amphiphysin (AMPH) and neurofascin (NFASC) are overexpressed in TB meningitis [<xref ref-type="bibr" rid="scirp.33257-ref31">31</xref>]. Ferritin light chain [FTL) is downregulated in TB meningitis [<xref ref-type="bibr" rid="scirp.33257-ref31">31</xref>].</p><p>Infection with Mycobacterium tuberculosis results in activation of caspase-1 and IL-1β secretion [<xref ref-type="bibr" rid="scirp.33257-ref32">32</xref>]. Potassium efflux and the lysosomal proteases cathepsin B and cathepsin L are required for the Mycobacterium tuberculosis-induced caspase-1 activation and IL-1β production [<xref ref-type="bibr" rid="scirp.33257-ref32">32</xref>]. Tumour necrosis factor-α causes caspase-1 cleavage and IL-1β secretion [<xref ref-type="bibr" rid="scirp.33257-ref32">32</xref>]. In addition, there is also a rise of NLRP3 inflammasome (composed of NLRP3, ASC, and cysteine protease caspase-1) [<xref ref-type="bibr" rid="scirp.33257-ref32">32</xref>].</p><p>TB meningitis patients have higher serum vascular endothelial growth factor (VEGF) level [<xref ref-type="bibr" rid="scirp.33257-ref33">33</xref>]. Increase in VEGF level is associated with shorter duration of illness, MRI features of stroke, and paradoxical response [<xref ref-type="bibr" rid="scirp.33257-ref33">33</xref>].</p><p>In summary, biomarkers such as TNF-α, IL-6, IL-10, IFN-alpha and IFN-gamma aid with the diagnosis of TB meningitis.</p></sec><sec id="s2_6"><title>2.6. Treatment and Management</title><p>Prompt diagnosis and early treatment are crucial [<xref ref-type="bibr" rid="scirp.33257-ref5">5</xref>]. Decision to start antituberculous treatment is often empirical [<xref ref-type="bibr" rid="scirp.33257-ref5">5</xref>]. WHO guidelines recommend a 6 months course of antituberculous treatment; however, other guidelines recommend a prolonged treatment extended to 9 or 12 months [<xref ref-type="bibr" rid="scirp.33257-ref5">5</xref>]. The recent British Infection Society guidelines indicate that treatment for TBM should comprise isoniazid, rifampicin, pyrazinamide and ethambutol for two months followed by isoniazid and rifampicin for at least 10 months [<xref ref-type="bibr" rid="scirp.33257-ref6">6</xref>]. Isoniazid is the most important of the first-line agents because of excellent CSF penetration and high bactericidal activity [<xref ref-type="bibr" rid="scirp.33257-ref34">34</xref>].</p><p>Streptomycin can be used instead of ethambutol as the fourth anti-TB agent but none of the drugs penetrates the CSF well in the absence of inflammation [<xref ref-type="bibr" rid="scirp.33257-ref34">34</xref>]. Other second-line therapy options includes ethionamide (bactericidal), cycloserine (bacteriostatic), para-aminosalicylic acid (bacteriostatic), aminoglycosides such amikacin (bactericidal), capreomycin (bacteriostatic), and thiacetazone (bacteriostatic) [<xref ref-type="bibr" rid="scirp.33257-ref34">34</xref>]. Ethionamide,is used in South Africa [<xref ref-type="bibr" rid="scirp.33257-ref35">35</xref>].</p><p>A recent study showed that a higher dose of rifampicin (600 mg, or 13 mg/kg) and standard-dose (400 mg daily) or high-dose moxifloxacin (800 mg daily) during the first two weeks is safe in patients with TB meningitis [<xref ref-type="bibr" rid="scirp.33257-ref36">36</xref>]. High dose intravenous rifampicin is associated with reduced mortality in TB meningitis patients with advanced disease [<xref ref-type="bibr" rid="scirp.33257-ref36">36</xref>].</p><p>The emergence of drug resistant tuberculosis poses a serious threat to the control of TB, and the development of drugs against the resistant strains is essential [<xref ref-type="bibr" rid="scirp.33257-ref1">1</xref>]. Resistance to antituberculous medications is associated with a high mortality [<xref ref-type="bibr" rid="scirp.33257-ref5">5</xref>].</p><p>Corticosteroids (dexamethasone) with antituberculous treatment reduce mortality and morbidity [1,5,6,23,37,38]. Adjunctive corticosteroid therapy more than two weeks improves survival, but treatment for more than 4 four weeks of use do not have effect on mortality [<xref ref-type="bibr" rid="scirp.33257-ref38">38</xref>]. Aspirin also reduces mortality [<xref ref-type="bibr" rid="scirp.33257-ref39">39</xref>]. Corticosteroids reduce the proportion of stroke after two months [<xref ref-type="bibr" rid="scirp.33257-ref11">11</xref>]. Corticosteroids result in decrease of hydrocephalus an stroke, therefore may affect clinical outcome [<xref ref-type="bibr" rid="scirp.33257-ref11">11</xref>]. Corticosteroids results in decrease of maturation of IL-1β through inhibition of mitochondrial reactive oxygen species generation [<xref ref-type="bibr" rid="scirp.33257-ref32">32</xref>]. Corticosteroids also reduce inflammasome activation [<xref ref-type="bibr" rid="scirp.33257-ref32">32</xref>].</p><p>Patients with hydrocephalus might require ventriculo-peritoneal shunting [<xref ref-type="bibr" rid="scirp.33257-ref5">5</xref>]. Bacillus Calmette-Gu&#233;rin [BCG) vaccination protects to some degree against tuberculous meningitis in children [<xref ref-type="bibr" rid="scirp.33257-ref5">5</xref>].</p></sec><sec id="s2_7"><title>2.7. Complications and Prognosis</title><p>The patients with TB meningitis with hydrocephalus will have worse prognosis and greater mortality [<xref ref-type="bibr" rid="scirp.33257-ref40">40</xref>]. The factors that are associated with hydrocephalus are stage three of disease, duration of illness (more than two months), and presence of neurological deficits such as, weakness with disability [<xref ref-type="bibr" rid="scirp.33257-ref40">40</xref>]. The presence of clinical features, such as, double vision, convulsions, visual blurring, papilloedema, and cranial nerve palsies are also positively associated with hydrocephalus [<xref ref-type="bibr" rid="scirp.33257-ref40">40</xref>]. CSF total cell count (more than 100/cu.mm), and CSF protein &gt; 2.5 g/l are also associated with the presence of hydrocephalus [<xref ref-type="bibr" rid="scirp.33257-ref40">40</xref>]. Patients with TB meningitis with hydrocephalus requiring cerebrospinal diversion had a higher risk of significant short-term mortality [<xref ref-type="bibr" rid="scirp.33257-ref41">41</xref>].</p><p>Neuroimaging factors that are significantly associated with hydrocephalus are basal exudates, tuberculoma and strokes [<xref ref-type="bibr" rid="scirp.33257-ref40">40</xref>]. Multivariate analysis demonstrated that visual impairment, cranial nerve palsy and the presence of basal exudates as significant predictors of hydrocephalus [<xref ref-type="bibr" rid="scirp.33257-ref40">40</xref>]. Some patients with early TB meningitis can possibly have complete resolution of hydrocephalus [<xref ref-type="bibr" rid="scirp.33257-ref40">40</xref>].</p><p>The presence of stroke on admission, Glasgow coma scale ≤ 8 on admission, age of ≥30 years and presence of hydrocephalus with ventriculo-peritoneal shunt was significantly associated with mortality [<xref ref-type="bibr" rid="scirp.33257-ref41">41</xref>]. There was increased mortality according to British Medical Research Council grade with statistical significance [<xref ref-type="bibr" rid="scirp.33257-ref41">41</xref>]. TBM with hydrocephalus which needed cerebrospinal diversion had a higher risk of significant short-term mortality [<xref ref-type="bibr" rid="scirp.33257-ref41">41</xref>].</p><p>Poor conscious state was significantly associated with poor prognosis in TB meningitis patients [38,42]. Severity of disease at admission and delayed anti-tuberculous therapy was related to poor outlook for TB meningitis patients [<xref ref-type="bibr" rid="scirp.33257-ref38">38</xref>].</p><p>1/5 of the patients have complete neurological recovery in one year occur in 1/5, but only 50% of them are independent for activities of daily living [<xref ref-type="bibr" rid="scirp.33257-ref43">43</xref>]. As for the rest of the patients, they have neurological sequelae, such as, cognitive impairment, motor deficit, optic atrophy and other cranial nerve palsies [<xref ref-type="bibr" rid="scirp.33257-ref43">43</xref>]. Motor deficit on admission, such as hemiparesis, is the most important predictor of neurologic deficits in one year [42,43]. GCS score is a good predictor of cognitive and motor sequelae [<xref ref-type="bibr" rid="scirp.33257-ref39">39</xref>]. Sequelae are common in patients who have focal motor weakness, change of sensorium at admission and GCS level [<xref ref-type="bibr" rid="scirp.33257-ref43">43</xref>]. Cognitive impairment is significantly associated with exudates and tuberculomas [<xref ref-type="bibr" rid="scirp.33257-ref42">42</xref>]. Motor deficits are significantly correlated with strokes [<xref ref-type="bibr" rid="scirp.33257-ref42">42</xref>].</p><p>Positive TB culture and polymerase chain reaction of CSF are factors associated with poor prognosis [<xref ref-type="bibr" rid="scirp.33257-ref38">38</xref>].</p><p>Serial CT scan at three and six months is abnormal in most TB meningitis patients [<xref ref-type="bibr" rid="scirp.33257-ref42">42</xref>]. At six months, hydrocephalus, tuberculomas and exudates will disappear but changes of stroke remain the same [<xref ref-type="bibr" rid="scirp.33257-ref42">42</xref>].</p><p>A third of patients with TB meningitis may deteriorate within six weeks of initiation of treatment [<xref ref-type="bibr" rid="scirp.33257-ref42">42</xref>]. Worsening on treatment is related to motor weakness and GCS on admission [<xref ref-type="bibr" rid="scirp.33257-ref42">42</xref>]. Age less than one year old and presence of severe TB are risk factors for failure of antituberculous therapy [<xref ref-type="bibr" rid="scirp.33257-ref44">44</xref>].</p></sec></sec><sec id="s3"><title>3. Conclusions</title><p>The diagnosis of TB meningitis is difficult because of nonspecific presentation and clinical features. Good prognosis depends on prompt diagnosis (before further neurological deterioration) with treatment; therefore radiological findings are very important. A recent study has shown that high dose intravenous rifampicin (800 mg daily) is associated with reduced mortality in patients with advanced disease.</p><p>Analysis of biomarkers in TB meningitis is important. There is an increase in the levels of serum and CSF TNF- α and IFN-γ in TB meningitis patients. IL-6 level is also increased in patients with tuberculoma and exudates. There is also a rise in the levels of IL-8, IFN-alpha, IFN-gamma, IL-10, CSF matrix metalloproteinases, CSF tissue inhibitors of matrix Metalloproteinases, VEGF level, caspase-1 and IL-1β. Signal-regulatory protein alpha is overexpressed at mRNA level.</p><p>There is advancement of research for TB meningitis. The TB meningitis research is rapidly progressing. In future, we will be able to see the development with respect to treatment and management of disease. Through the knowledge of biomarkers, better and more advanced antituberculous therapy can be developed.</p></sec><sec id="s4"><title>REFERENCES</title></sec><sec id="s5"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.33257-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">R. Galimi, “Extrapulmonary Tuberculosis: Tuberculous Meningitis New Developments,” European Review for Medical and Pharmacological Sciences, Vol. 15, No. 4, 2011, pp. 365-386.</mixed-citation></ref><ref id="scirp.33257-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">R. Abdelmalek, F. Kanoun, B. Kilani, H. Tiouiri, F. Zouiten, A. Ghoubantini and T. B. Chaabane, “Tuberculous Meningitis in Adults: MRI Contribution to the Diagnosis in 29 Patients,” International Journal of Infectious Diseases, Vol. 10, No. 5, 2006, pp. 372-377.  
doi:10.1016/j.ijid.2005.07.009</mixed-citation></ref><ref id="scirp.33257-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">L. Chaidir, A. R. Ganiem, A. V. Zanden, S. Muhsinin, T. Kusumaningrum, I. Kusumadewi, A. van der Ven, B. Alisjahbana, I. Parwati and R. van Crevel, “Comparison of Real Time IS6110-PCR, Microscopy, and Culture for Diagnosis of Tuberculous Meningitis in a Cohort of Adult Patients in Indonesia,” PLoS One, Vol. 7, No. 12, 2012, Article ID: e52001. doi:10.1371/journal.pone.0052001</mixed-citation></ref><ref id="scirp.33257-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">B. Lakatos, G. Prinz, C. Sárvári, K. Kamotsay, P. Molnár, A. Abrahám and J. Budai, “Central Nervous System Tuberculosis in Adult Patients,” Orvosi Hetilap, Vol. 152, No. 15, 2011, pp. 588-596. doi:10.1556/OH.2011.29076</mixed-citation></ref><ref id="scirp.33257-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">R. K. Garg, “Tuberculous Meningitis,” Acta Neurologica Scandinavica, Vol. 122, No. 2, 2010, pp. 75-90.</mixed-citation></ref><ref id="scirp.33257-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Y. Suzuki, “Tuberculosis Infection in the Nervous System,” Nihon Rinsho, Vol. 69, No. 8, 2011, pp. 1422-1426.</mixed-citation></ref><ref id="scirp.33257-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">M. E. Hurmuzache, C. Luca, I. Lovin and C. Dorobat, “Tuberculosis Meningo-Encephalitis with Positive CSF for KB and Slowly Favourable Evolution. Case Report,” Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, Vol. 116, No. 3, 2012, pp. 804-807.</mixed-citation></ref><ref id="scirp.33257-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">G. E. Thwaites and T. T. Hien, “Tuberculous Meningitis: Many Questions, Too Few Answers,” The Lancet Neurology, Vol. 4, No. 3, 2005, pp. 160-170.</mixed-citation></ref><ref id="scirp.33257-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">M. R. R. Bullock and J. M. Welchman, “Diagnostic and Prognostic Features of Tuberculous Meningitis of CT Scanning,” Journal of Neurology, Neurosurgery &amp; Psychiatry, Vol. 45, No. 12, 1982, pp. 1098-1101.  
doi:10.1136/jnnp.45.12.1098</mixed-citation></ref><ref id="scirp.33257-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">R. Kumar, S. N. Singh and N. Kohli, “A diagnostic rule for tuberculous meningitis,” Archives of Disease in Childhood, Vol. 81, No. 3, 1999, pp. 221-224.  
doi:10.1136/adc.81.3.221</mixed-citation></ref><ref id="scirp.33257-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">G. E. Thwaites, T. T. Chau, K. Stepniewska, N. H. Phu, L. V. Chuong, D. X. Sinh, N. J. White, C. M. Parry and J. J. Farrar, “Diagnosis of Adult Tuberculous Meningitis by Use of Clinical and Laboratory Features,” Lancet, Vol. 360, No. 9342, 2002, pp. 1287-1292.  
doi:10.1016/S0140-6736(02)11318-3</mixed-citation></ref><ref id="scirp.33257-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">A. Moghtaderi, R. Alavi-Naini, S. Izadi and L. E. Cuevas,  “Diagnostic Risk Factors to Differentiate Tuberculous and Acute Bacterial Meningitis,” Scandinavian Journal of Infectious Diseases, Vol. 41, No. 3, 2009, pp. 188-194.  
doi:10.1080/00365540902721384</mixed-citation></ref><ref id="scirp.33257-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">G. K. Ahuja, K. K. Mohan, K. Prasad and M. Behari, “Diagnostic Criteria for Tuberculousmeningitis and Their Validation,” Tubercle and Lung Disease, Vol. 75, No. 2, 1994, pp. 149-152. doi:10.1016/0962-8479(94)90045-0</mixed-citation></ref><ref id="scirp.33257-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">G. E. Thwaites, T. T. Chau and J. J. Farrar, “Improving the Bacteriological Diagnosis of Tuberculous Meningitis,” Journal of Clinical Microbiology, Vol. 42, No. 1, 2004, pp. 378-379. doi:10.1128/JCM.42.1.378-379.2004</mixed-citation></ref><ref id="scirp.33257-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">S. Haldar, N. Sharma, V. K. Gupta and J. S. Tyagi, “Efficient Diagnosis of Tuberculous Meningitis by Detection of Mycobacterium Tuberculosis DNA in Cerebrospinal Fluid Filtrates Using PCR,” Journal of Medical Microbiology, Vol. 58, Pt. 5, 2009, pp. 616-624.  
doi:10.1099/jmm.0.006015-0</mixed-citation></ref><ref id="scirp.33257-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">A. Hannan, A. Hafeez, S. Chaudary and M. Rashid, “Rapid Confirmation of Tuberculous Meningitis in Children by Liquid Culture Media,” Journal of Ayub Medical College, Abbottabad, Pakistan, Vol. 22, No. 4, 2010, pp. 171-175.</mixed-citation></ref><ref id="scirp.33257-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">P. García, L. Bahamondes, P. Reyes, J. C. Román, H. Poblete and M. E. Balcells, “A Comparative Study for Adenosine Deaminase and Anti-Antigen A-60 Antibodies Detection for the Diagnosis of Tuberculous Meningitis,” Revista Chilena de Infectología, Vol. 29, No. 5, 2012, pp. 521-526. doi:10.4067/S0716-10182012000600007</mixed-citation></ref><ref id="scirp.33257-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">D. H. Kennedy and R. J. Fallon, “Tuberculous Meningitis,” JAMA, Vol. 241, No. 3, 1979, pp. 264-268.  
doi:10.1001/jama.1979.03290290032021</mixed-citation></ref><ref id="scirp.33257-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">P. R. Donald and J. F. Schoeman, “Tuberculous Meningitis,” New England Journal of Medicine, Vol. 351, 2004, p. 17.</mixed-citation></ref><ref id="scirp.33257-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">D. K. Dastur, D. K. Manghani and P. M. Udani, “Pathology and Pathogenetic Mechanisms in Neurotuberculosis,” Radiologic Clinics of North America, Vol. 33, No. 4, 1995, pp. 733-752.</mixed-citation></ref><ref id="scirp.33257-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">G. A. Lammie, R. H. Hewlett, J. F. Schoeman and P. R. Donald, “Tuberculous Cerebrovascular Disease: A Review,” Journal of Infection, Vol. 59, No. 3, 2009, pp. 156-166. doi:10.1016/j.jinf.2009.07.012</mixed-citation></ref><ref id="scirp.33257-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">D. K. Dastur, “The Pathology and Pathogenesis of Tuberculous Encephalopathy and Radiculomyelopathy: A Comparison with Allergic Encephalomyelitis,” Child’s Nervous System, Vol. 2, No. 1, 1986, pp. 13-19.   
doi:10.1007/BF00274027</mixed-citation></ref><ref id="scirp.33257-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">F. Y. Hsieh, L. G. Chia and W. C. Shen, “Locations of Cerebral Infarctions in Tuberculousmeningitis,” Neuroradiology, Vol. 34, No. 3, 1992, pp. 197-199.  
doi:10.1007/BF00596334</mixed-citation></ref><ref id="scirp.33257-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">K. L. Roos, “Pearls and Pitfalls in the Diagnosis and Management of Central Nervous System Infectious Diseases,” Seminars in Neurology, Vol. 18, No. 2, 1998, pp. 185-196. doi:10.1055/s-2008-1040872</mixed-citation></ref><ref id="scirp.33257-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">U. K. Misra, J. Kalita and P. K. Maurya, “Stroke in Tuberculous Meningitis,” Journal of the Neurological Sciences, Vol. 303, No. 1, 2011, pp. 22-30.  
doi:10.1016/j.jns.2010.12.015</mixed-citation></ref><ref id="scirp.33257-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">P. Nair, J. Kalita, S. Kumar and U. K. Misra, “MRI Pattern of Infarcts in Basal Ganglia Region in Patients with Tuberculous Meningitis,” Neuroradiology, Vol. 51, No. 4, 2009, pp. 221-225. doi:10.1007/s00234-009-0495-x</mixed-citation></ref><ref id="scirp.33257-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">M. Wasay, B. A. Kheleani, M. K. Moolani, J. Zaheer, M. Pui, S. Hasan, et al., “Brain CT and MRI Findings in 100 Consecutive Patients with Intracranial Tuberculoma,” Journal of Neuroimaging, Vol. 13, No. 3, 2003, pp. 240-247.</mixed-citation></ref><ref id="scirp.33257-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">P. B. Kingsley, T. C. Shah and R. Woldenberg, “Identification of Diffuse and Focal Brain Lesions by Clinical Magnetic Resonance Spectroscopy,” NMR in Biomedicine, Vol. 19, No. 4, 2006, pp. 435-462. doi:10.1002/nbm.1039</mixed-citation></ref><ref id="scirp.33257-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">U. K. Misra, J. Kalita, R. Srivastava, P. P. Nair, M. K.  Mishra and A. Basu, “A Study of Cytokines in Tuberculous Meningitis: Clinical and MRI Correlation,” Neuroscience Letters, Vol. 483, No. 1, 2010, p. 610.  
doi:10.1016/j.neulet.2010.07.029</mixed-citation></ref><ref id="scirp.33257-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">G. N. Babu, A. Kumar, J. Kalita and U. K. Misra, “Proinflammatory Cytokine Levels in the Serum and Cerebrospinal Fluid of Tuberculous Meningitis Patients,” Neuroscience Letters, Vol. 436, No. 1, 2008, pp. 48-51.  
doi:10.1016/j.neulet.2008.02.060</mixed-citation></ref><ref id="scirp.33257-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">S. G. Kumar, A. K. Venugopal, A. Mahadevan, S. Renuse, G. H. Harsha, N. A. Sahasrabuddhe,  H. Pawar, R. Sharma, P. Kumar, S. Rajagopalan, K. Waddell, Y. L. Ramachandra, P. Satishchandra, R. Chaerkady, K. T. Prasad, S. K. Shankar and A. Pandey, “Quantitative Proteomics for Identifying Biomarkers for Tuberculous Meningitis,” Clinical Proteomics, Vol. 9, No. 1, 2012, p. 12. doi:10.1186/1559-0275-9-12</mixed-citation></ref><ref id="scirp.33257-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">H. M. Lee, J. Kang, S. J. Lee and E. K. Jo, “Microglial Activation of the NLRP3 Inflammasome Bythe Priming Signals Derived from Macrophages Infected with Mycobacteria,” Glia, Vol. 61, No. 3, 2013, pp. 441-452.  
doi:10.1002/glia.22448</mixed-citation></ref><ref id="scirp.33257-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">U. K. Misra, J. Kalita, A. P. Singh and S. Prasad, “Vascular Endothelial Growth Factor in Tuberculous Meningitis,” International Journal of Neuroscience, Vol. 123, No. 2, 2013, pp. 128-132.</mixed-citation></ref><ref id="scirp.33257-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">G. E. Marx and E. D. Chan, “Tuberculous Meningitis: Diagnosis and Treatment Overview,” Tuberculosis Research and Treatment, Vol. 2011, 2011, Article ID: 798764.</mixed-citation></ref><ref id="scirp.33257-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">G. Thwaites, M. Fisher, C. Hemingway, G. Scott, T. Solomon and J. Innes, “British Infection Society Guidelines for the Diagnosis and Treatment of Tuberculosis of the Central Nervous System in Adults and Children”.  
www.elsevierhealth.com/journals/jinf</mixed-citation></ref><ref id="scirp.33257-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">R. Ruslami, A. R. Ganiem, S. Dian, L. Apriani, T. H. Achmad, A. J. van der Ven, G. Borm, R. E. Aarnoutse and R. van Crevel, “Intensified Regimen Containing Rifampicin and Moxifloxacin for Tuberculous Meningitis: An Open-Label, Randomised Controlled Phase 2 Trial,” Lancet Infectious Disease, Vol. 13, No. 1, 2013, pp. 27-35. doi:10.1016/S1473-3099(12)70264-5</mixed-citation></ref><ref id="scirp.33257-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">G. N. Babu, A. Kumar, J. Kalita and U. K. Misra, “Proinflammatory Cytokine Levels in the Serum and Cerebrospinal Fluid of Tuberculous Meningitis Patients,” Neuroscience Letters, Vol. 436, No. 1, 2008, pp. 48-51.  
doi:10.1016/j.neulet.2008.02.060</mixed-citation></ref><ref id="scirp.33257-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">P. C. Hsu, C. C. Yang, J. J. Ye, P. Y. Huang, P. C. Chiang and M. H. Lee, “Prognostic Factors of Tuberculous Meningitis in Adults: A 6-Year Retrospective Study at a Tertiary Hospital in Northern Taiwan,” Journal of Microbiology, Immunology and Infection, Vol. 43, No. 2, 2010, pp. 111-118.</mixed-citation></ref><ref id="scirp.33257-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">G. A. Lammie, R. H. Hewlett, J. F. Schoeman and P. R. Donald, “Tuberculous Cerebrovascular Disease: A Review,” Journal of Infection, Vol. 59, No. 3, 2009, pp. 156-166. doi:10.1016/j.jinf.2009.07.012</mixed-citation></ref><ref id="scirp.33257-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">T. Raut, R. K. Garg, A. Jain, R. Verma, M. K. Singh, H. S. Malhotra, N. Kohli and A. Parihar, “Hydrocephalus in Tuberculous Meningitis: Incidence, Its Predictive Factors and Impact on the Prognosis,” Journal of Infection, Vol. 66, No. 4, 2013, pp. 330-337.</mixed-citation></ref><ref id="scirp.33257-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">T. C. Morgado, M. Kinsky, H. Carrara, S. Rothemeyer and P. Semple, “Prognostic Value of Computed Tomography-Evident Cerebral Infarcts in Adult Patients with Tuberculous Meningitis and Hydrocephalus Treated with an External Ventricular Drain,” World Neurosurgery, 2012.</mixed-citation></ref><ref id="scirp.33257-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">P. Ranjan, J. Kalita and U. K. Misra, “Serial Study of Clinical and CT Changes in Tuberculous Meningitis,” Neuroradiology, Vol. 45, No. 5, 2003, pp. 277-282.</mixed-citation></ref><ref id="scirp.33257-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">J. Kalita, U. K. Misra and P. Ranjan, “Predictors of Long-Term Neurological Sequelae of Tuberculous Meningitis: A Multivariate Analysis,” European Journal of Neurology, Vol. 14, No. 1, 2007, pp. 33-37.  
doi:10.1111/j.1468-1331.2006.01534.x</mixed-citation></ref><ref id="scirp.33257-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">X. R. Wu, Q. Q. Yin, A. X. Jiao, B. P. Xu, L. Sun, W. W. Jiao, J. Xiao, Q. Miao, C. Shen, F. Liu, D. Shen and A. Shen, “Pediatric Tuberculosis at Beijing Children’s Hospital: 2002-2010,” Paediatrics, Vol. 130, No. 6, 2012, pp. e1433-e1440. doi:10.1542/peds.2011-3742</mixed-citation></ref></ref-list></back></article>